
A Review of Clinical Trial Data on the Recombinant Zoster Vaccine




Background

zoster (HZ) >90%

patient populations, including immunocompromised individuals



To review published RZV clinical trial data since publication of the original ZOE trials^{1,3}




Methods

A literature review was performed in November 2021 using PubMed

'recombinant') AND ('study' OR 'trial') AND 'GSK'

Year range: 2015–2021





34 RZV clinical studies since publication of the ZOE trials



Adults aged ≥50 years:

	Addits aged 200 years.	
	Safety, reactogenicity and immunogenicity with standard RZV administration	
	Efficacy against HZ, PHN, non-PHN complications**	
	Long-term efficacy, immunogenicity and/or safety [†]	
	Impact on quality of life (QoL)	
	Co-administration with another vaccine	
	Different schedules; different routes of administration	
	Individuals with prior ZVL vaccination	
	Individuals with prior history of HZ	1 st
	Frail individuals	1 st
	Individuals with pre-existing potential immune-mediated diseases (pIMDs)	1 st
	Individuals with pre-existing comorbidities	1 st
	Immunocompromised adults aged ≥18 years:	
	Autologous haematopoietic stem cell transplantation (aHSCT) recipients	
	Solid tumours	1 st
	Renal transplant	1 st
		1 st
	Haematological malignancies	1 50

** Non-PHN complications: #* On-chemo group (1st dose administered 8-20 years from the pooled ZOE-50/70 analysis; ** Non-PHN complications: HZ vasculitis, disseminated HZ, stroke, ophthalmic, neurologic, and visceral diseases; *5-10 years from the pooled ZOE-50/70 analysis; ** Non-PHN complications: HZ vasculitis, disseminated HZ, stroke, ophthalmic, neurologic, and visceral diseases; ** Non-PHN complications: HZ vasculitis, disseminated HZ, stroke, ophthalmic, neurologic, and visceral diseases; *5-10 years post-dose 2 to 1 years post-dose 1 or 2; ** On-chemo group (1st dose on the day of chemotherapy); * Non-PHN complications: HZ vasculitis, disseminated HZ, stroke, ophthalmic, neurologic, and visceral diseases; ** Non-PHN complications: HZ vasculitis, disseminated HZ, stroke on the day of chemotherapy); ** On-chemo group (1st dose on t in RZV arm, 12.2% SAEs in placebo arm; §Based on Zoster Brief Pain Inventory (ZBPI) worst pain score; Based on ZBPI activities of daily living (ADL) scores.

ster: attologicals SA (study identifier: 214093). Abbreviations; CD4: cluster of differentiation; HZ: herpes zoster; attologous haematopoietic stem cell transplantation; CD4: cluster of differentiation; HZ: herpes zoster; attologous haematopoietic stem cell transplantation; CD4: cluster of differentiation; HZ: herpes zoster; attologous haematopoietic stem cell transplantation; CD4: cluster of differentiation; CD4: cluster of differentiation; CD4: cluster of differentiation; CD4: cluster of differentiation; HZ: herpes zoster; attologous haematopoietic stem cell transplantation; CD4: cluster of differentiation; CD4: clust tetanus, tetanus, and pertussis vaccine; **BR:** interquartile range; **BR:** interquartile range; **BR:** interquartile range; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster Vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-attenuated zoster Vaccine; **BPI:** Zoster Brief Pain Inventory; **ZVL:** live-a the et al. *N Engl J Med* 2015;372:2087–2096; **1**. Lal H, et al. *J Infect Dis*; 2021 doi: 10.1093/infdis/jiab536; **5**. Colindres R, et al. *J Infect Dis*; 2021 doi: 10.1093/infdis/jiab536; **5**. Colindres R, et al. *N Engl J Med* 2015;372:2087–2096; **7**. López-Fauqued M, et al. *J Infect Dis*; 2021 doi: 10.1093/infdis/jiab536; **5**. Colindres R, et al. *J Infect Dis*; 2021 doi: 10.1093/infdis/jiab536; **5**. Colindres R, et al. *J Infect Dis*; 2021 doi: 10.1093/infdis/jiab536; **5**. Colindres R, et al. *J Infect Dis*; 2021 doi: 10.1093/infdis/jiab536; **5**. Colindres R, et al. *J Infect Dis*; 2021 doi: 10.1093/infdis/jiab536; **5**. Colindres R, et al. *J Infect Dis*; 2021; 39:6–10; and the end of the end to the end of the Hum Vaccine 2018;36:1537–1541; 12. Willer DO, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467 14. Chlibek R, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467 14. Chlibek R, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467 14. Chlibek R, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467 14. Chlibek R, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;76:485–490; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;76:485–490; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;76:485–490; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;76:485–490; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;76:485–490; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2019;74:1231–1238; 18. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol Sci Med Sci Med Sci 2021;74:1459–1467; 19. Schmader KE, et al. J Gerontol A Biol S Ender Dis 2017; 216:1343–1351; 27. Godeaux O, et al. J Infect Dis 2017; 216:1352–1361; 27. Corran D, et al. J Infect Dis 2017; 216:1343–1351; 27. Godeaux O, et al. J Infect Dis 2017; 13:574–578; 27. Codeaux O, et al. J Infect Dis 2017; 13:574–578; 27. Codeaux O, et al. J Infect Dis 2017; 13:1051–1058; 28. Curran D, et al. J Infect Dis 2017; 13:1051–1058; 28. Curran D, et al. J Infect Dis 2017; 216:1343–1351; 27. Godeaux O, et al. J Infect Dis 2017; 13:1051–1058; 28. Curran D, et al. J Infect Dis 2017; 28. Curran D, et al. J Infect Dis 2017; 28. Curran D, et al. J Infect Dis 2017; 28. Curran D, et al. J Infect Dis 2017; 28. Curran D, et al. J Infect Dis 2017; 28. Curran D, et al. J Infect Dis 2017; 28. Curran D, et al. J Infect Dis 2017; 28. Curran D, et al. J Infect Dis 2017; 28. Curr al. Hum Vaccin Immunother 2019;15:2865–2872; 31. Bastidas A, et al. Clin Infect Dis 2020;70:181–190; 36. Dagnew AF, et al. Lancet Infect Dis 2019;125:1301–1312; 35. Vink P, et al. Clin Infect Dis 2020;70:181–190; 36. Dagnew AF, et al. Lancet Infect Dis 2019;125:1301–1312; 35. Vink P, et al. Clin Infect Dis 2020;70:181–190; 36. Dagnew AF, et al. Lancet Infect Dis 2019;125:2474–2481; 33. Vink P, et al. Clin Infect Dis 2019;125:1301–1312; 35. Vink P, et al. Clin Infect Dis 2019;125:2474–2481; 33. Vink P, et al. Clin Infect Dis 2019;125:1301–1312; 35. Vink P,

Presenting author: Claire O'Reilly, claire.a.o'reilly@gsk.com

<u>Claire O'Reilly</u>¹ on behalf of Nicolas Lecrenier,² Inga Posiuniene,² Desmond Curran² ¹GSK, Dublin, Ireland; ²GSK, Wavre, Belgium

IDSI ASM 2023 | 18–19 May 2023 | Dublin, Ireland